Loading
companiesCompany
Helsinn
Helsinn is a Swiss family-owned company focused on supportive cancer care: the antiemetics Aloxi and Akynzeo, and the topical nitrogen mustard Valchlor for cutaneous T-cell lymphoma.
Overview
Helsinn, a Swiss family-owned company based in Lugano, focuses on supportive cancer care with the antiemetics Aloxi and Akynzeo and the topical nitrogen mustard Valchlor for cutaneous T-cell lymphoma. It developed palonosetron, sold as Aloxi, and the netupitant and palonosetron fixed combination, sold as Akynzeo, for chemotherapy-induced nausea and vomiting, and acquired Valchlor, a mechlorethamine gel for mycosis fungoides, licensing its products to partners such as Eisai in the United States and Recordati in Europe. OnCo links it to palonosetron, netupitant and palonosetron, and mechlorethamine. Whether supportive care products can sustain an independent company as generics arrive is the open question. Each product has its own page.
Headquarters
Lugano, CH
Scorecard
All companies#88of 1244 companies, score 53
- approved products +18
- targets +2
- modalities +4
- regions +2
- registry trials +30
- failures -3
3 approved, 0 in phase 3, 0 earlier, 1 targets, 3,773 registry studies. Formula on the scorecards page.
Type
Website
WithdrawnOral FGFR1 to 3 kinase inhibitor
Infigratinib · Truseltiq
Infigratinib is an FGFR inhibitor pill given accelerated approval in the United States in 2021 for bile duct cancer with an FGFR2 fusion, then withdrawn in 2024 when its confirmatory trial could not enrol; it is now being developed for achondroplasia instead.
ApprovedAlkylating agent (nitrogen mustard); intravenous and topical gel
Mechlorethamine (chlormethine) · Mustargen (historic) / Valchlor gel
Mechlorethamine, or nitrogen mustard, was the first chemotherapy ever used, in 1940s Hodgkin lymphoma. Today its main use is as a skin gel (Valchlor in the US, Ledaga in Europe) for early cutaneous T-cell lymphoma.
ApprovedFixed combination NK1 antagonist plus 5-HT3 antagonist (antiemetic)
Netupitant and palonosetron · Akynzeo
Akynzeo combines two anti-sickness drugs in one capsule or infusion taken once before chemotherapy, so a single dose plus dexamethasone protects against both immediate and delayed vomiting.
ApprovedSecond-generation 5-HT3 receptor antagonist (antiemetic)
Palonosetron · Aloxi
Palonosetron (Aloxi) is a long-acting anti-sickness injection given once before chemotherapy; a single dose covers both the first day and the delayed nausea that follows.
Similar pages
- TreatmentAprepitant (and fosaprepitant)
Shares Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC), Netupitant and palonosetron, Palonosetron.
- TrialTreatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
Shares Netupitant and palonosetron, Palonosetron.
- TreatmentOndansetron
Shares Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC), Palonosetron.
- TermSkin-directed therapy in mycosis fungoides: creams, light and small radiotherapy fields
Shares Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides, Mechlorethamine (chlormethine).
- TechnologyAntiemetics for chemotherapy-induced nausea and vomiting
Shares Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC), Netupitant and palonosetron, Palonosetron.
- CancerMycosis fungoides
Shares Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides, Mechlorethamine (chlormethine).
drugs
WithdrawnOral FGFR1 to 3 kinase inhibitor
Infigratinib · Truseltiq
ApprovedAlkylating agent (nitrogen mustard); intravenous and topical gel
Mechlorethamine (chlormethine) · Mustargen (historic) / Valchlor gel
ApprovedFixed combination NK1 antagonist plus 5-HT3 antagonist (antiemetic)
Netupitant and palonosetron · Akynzeo
ApprovedSecond-generation 5-HT3 receptor antagonist (antiemetic)
Palonosetron · Aloxi